IN2014MN00139A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00139A
IN2014MN00139A IN139MUN2014A IN2014MN00139A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A IN 139MUN2014 A IN139MUN2014 A IN 139MUN2014A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A
Authority
IN
India
Prior art keywords
endoxifen
formulations
diseases
breast
agents
Prior art date
Application number
Other languages
English (en)
Inventor
M Ali Shoukath
U Ahmad Moghis
Ahmad Ateeq
Sheikh Saifuddin
Ahmad Imran
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN00139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of IN2014MN00139A publication Critical patent/IN2014MN00139A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN139MUN2014 2006-11-21 2007-11-21 IN2014MN00139A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86042006P 2006-11-21 2006-11-21
US86078806P 2006-11-22 2006-11-22
PCT/US2007/085443 WO2008070463A2 (en) 2006-11-21 2007-11-21 Endoxifen methods and compositions

Publications (1)

Publication Number Publication Date
IN2014MN00139A true IN2014MN00139A (es) 2015-06-19

Family

ID=39492975

Family Applications (1)

Application Number Title Priority Date Filing Date
IN139MUN2014 IN2014MN00139A (es) 2006-11-21 2007-11-21

Country Status (11)

Country Link
US (2) US9333190B2 (es)
EP (1) EP2101731B1 (es)
JP (1) JP2010510327A (es)
CA (1) CA2669913C (es)
DK (1) DK2101731T3 (es)
ES (1) ES2665917T3 (es)
HU (1) HUE037109T2 (es)
IN (1) IN2014MN00139A (es)
PL (1) PL2101731T3 (es)
PT (1) PT2101731T (es)
WO (1) WO2008070463A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101731B1 (en) 2006-11-21 2018-01-31 Jina Pharmaceuticals Inc. Endoxifen for use in the treatment of cancer
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP2373305B1 (en) * 2008-12-11 2017-03-15 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
CN108096563A (zh) 2011-04-28 2018-06-01 肿瘤多肽股份公司 细胞毒性二肽的冻干制剂
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
NZ708016A (en) * 2012-10-26 2018-02-23 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
EP3322406A4 (en) * 2015-07-14 2019-06-12 Atossa Genetics Inc. TRANSPARENT METHODS AND COMPOSITIONS FOR THE TREATMENT OF MAMMARY DISEASES
DE102015222031A1 (de) 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) * 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
WO2019051370A1 (en) * 2017-09-11 2019-03-14 Atossa Genetics Inc. TOPICAL COMPOSITIONS AND METHODS OF TREATMENT
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3177260A1 (en) 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
US20220296518A1 (en) * 2021-03-18 2022-09-22 National Taiwan University Lipid-based nanoparticle delivery system for hydrophilic charged compound
MX2024008643A (es) 2022-01-12 2024-09-25 Atossa Therapeutics Inc Composiciones de (z)-endoxifeno y métodos de enriquecimiento de este.
WO2023211939A1 (en) * 2022-04-26 2023-11-02 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
ES2208687T3 (es) * 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP2001507207A (ja) * 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
PT2076244T (pt) 2006-10-10 2017-03-09 Jina Pharmaceuticals Inc Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos
WO2008048194A1 (en) 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
EP2088865B1 (en) 2006-11-06 2015-10-21 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
EP2101731B1 (en) 2006-11-21 2018-01-31 Jina Pharmaceuticals Inc. Endoxifen for use in the treatment of cancer
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
JP5720881B2 (ja) 2011-01-31 2015-05-20 東芝ライテック株式会社 Ledランプ点灯装置および照明装置

Also Published As

Publication number Publication date
ES2665917T3 (es) 2018-04-30
US20100112041A1 (en) 2010-05-06
CA2669913C (en) 2012-09-18
PL2101731T3 (pl) 2018-07-31
DK2101731T3 (en) 2018-04-16
WO2008070463A2 (en) 2008-06-12
HUE037109T2 (hu) 2018-08-28
PT2101731T (pt) 2018-04-18
US20160346230A1 (en) 2016-12-01
WO2008070463A9 (en) 2008-09-18
JP2010510327A (ja) 2010-04-02
EP2101731A2 (en) 2009-09-23
US10376479B2 (en) 2019-08-13
EP2101731A4 (en) 2011-04-20
CA2669913A1 (en) 2008-06-12
US9333190B2 (en) 2016-05-10
WO2008070463A3 (en) 2008-11-06
EP2101731B1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
IN2014MN00139A (es)
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2010014233A (es) Compuestos quimicos 251.
PH12014501560A1 (en) Carbamate compounds and of making and using same
UA107783C2 (en) Isoindoline compounds for use in treating cancer
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
GEP20125469B (en) Inhibitors of akt activity
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
GB0620385D0 (en) Novel compounds
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf